IBB mid-cap outperforms XBI mid-cap
In the mid-cap space by market cap, the top ten mid-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the top ten mid-cap stocks of the SPDR S&P Biotech ETF (XBI) for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.
The above graph reflects the performance of the top ten mid-cap stocks of IBB and XBI for the week ended September 4.
Intrexon underperforms, ISIS outperforms
Intrexon (XON) fell 11.57% for the week ended September 4, 2015. The stock fell on profit booking with low traded volumes. However, XON recently completed the public offering of common stocks and raised ~$230 million. The stock is trading below the 20-day, 50-day, and 100-day moving averages. XON has a weight of 0.90% in XBI.
United Therapeutics (UTHR) fell 7.02%. The stock went down on profit booking with high traded volumes on September 1, 2015. About 1.14 million shares traded that day.
UTHR stock closed at $149.21 on September 4, 2015, and was trading below the 20-day, 50-day, and 100-day moving averages. The stock is trading close to the lower Bollinger band price of $145 and might be oversold if the trend continues. UTHR has a weight of 1.24% in IBB and 1.11% in XBI.
On the positive side, ISIS Pharmaceuticals (ISIS) rose 1.09% for the week ended September 4, 2015, on high trading volumes. ISIS will present at the investor conferences held in Boston and New York on September 10, 18, and 30, 2015. ISIS has a weight of 1.15% in IBB and 0.94% in XBI.